Last $0.40 USD
Change Today -0.015 / -3.61%
Volume 143.3K
IBIO On Other Exchanges
Symbol
Exchange
NYSE Amex
As of 2:38 PM 07/25/14 All times are local (Market data is delayed by at least 15 minutes).

ibio inc (IBIO) Snapshot

Open
$0.38
Previous Close
$0.42
Day High
$0.43
Day Low
$0.38
52 Week High
01/21/14 - $0.85
52 Week Low
05/27/14 - $0.24
Market Cap
26.3M
Average Volume 10 Days
181.7K
EPS TTM
$-0.10
Shares Outstanding
65.6M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for IBIO INC (IBIO)

Related News

No related news articles were found.

ibio inc (IBIO) Related Businessweek News

No Related Businessweek News Found

ibio inc (IBIO) Details

iBio, Inc., a biotechnology company, focuses on the commercialization of its proprietary plant-based protein expression technologies in the United States and internationally. Its proprietary technologies include iBioLaunch, a transformative platform technology for the development and production of biologics; and iBioModulator, a technology platform that improves the potency and duration of the effect of prophylactic and therapeutic vaccines. The company’s product candidates include C1 Esterase Inhibitor, a preclinical stage plasma-derived protein; Alpha-Galactosidase, a preclinical orphan designation stage enzyme replacement; and Palivizumab, a preclinical stage monoclonal antibody for the therapeutic protein market. Its product candidates also comprise H1N1 Influenza and H5N1 Influenza viral disease vaccines that completed Phase I; Hookworm parasitic pathogen vaccine, which is in preclinical stage; and Human Papillomavirus therapeutic vaccine that is in preclinical stage. In addition, the company’s product candidates include Anthrax/Plague bacterial disease vaccine that is in preclinical stage; and Anthrax monoclonal antibody that is in preclinical stage for the Biodefense market. It has a collaboration agreement with Fraunhofer Center for Molecular Biology to perform research and development activities to develop the recombinant form of C1 esterase inhibitor; an alliance with GE Healthcare to commercialize its plant-based technologies for the manufacture of biopharmaceuticals and vaccines; a collaboration agreement granting FioCruz/Bio-Manguinhos a license to use its proprietary technology in connection with the development, manufacture, and commercialization of vaccine products; and a license and collaboration agreement enabling Caliber Biotherapeutics LLC to use its iBioLaunch platform in connection with the development of an undisclosed monoclonal antibody-based therapeutic protein for an oncology indication. The company is headquartered in Newark, Delaware.

9 Employees
Last Reported Date: 09/30/13

ibio inc (IBIO) Top Compensated Officers

Executive Chairman and Chief Executive Office...
Total Annual Compensation: $300.0K
President
Total Annual Compensation: $230.0K
Chief Scientific Officer
Total Annual Compensation: $200.0K
Compensation as of Fiscal Year 2013.

ibio inc (IBIO) Key Developments

iBio, Inc. Appoints Richard M. Silver to its Clinical Advisory Board

iBio, Inc. has appointed Richard M. Silver, M.D. to its recently formed clinical advisory board. He will provide iBio with guidance on further development and clinical trial design for the company's novel drug candidate for systemic sclerosis and other fibrotic diseases.

iBio, Inc. Appoints Timothy Blackwell to New Clinical Advisory Board

iBio, Inc. appointed Timothy Blackwell, M.D. to its newly formed clinical advisory board. He will provide iBio with guidance on further development and commercialization of the company's novel drug candidate for IPF and other fibrotic diseases. Blackwell is the Ralph and Lulu Owen Chair in Medicine at Vanderbilt University and Professor of Medicine, Cancer Biology, and Cell and Developmental Biology. He is the director of the division of Allergy, Pulmonary & Critical Care.

iBio Expands Commercial Collaboration with Bio-Manguinhos and Fraunhofer

iBio, Inc. amended its multiproduct license and collaboration agreement with Brazil's Bio-Manguinhos/Fiocruz and the Fraunhofer USA Center for Molecular Biotechnology to enable expansion of joint work on an iBioLaunch(TM)-produced recombinant yellow fever vaccine and other products. Yellow fever vaccine candidates based on iBio's proprietary technology, including virus-like particles (VLPs) and traditional antigen formulations, have been highly successful in rodent virus-challenge studies. Additional tasks to be performed include non-human primate studies, the completion of IND-enabling tests, and the establishment of a commercial technology transfer program to enable Bio-Manguinhos to produce a recombinant iBioLaunch-based yellow fever vaccine in the new facility designed for that purpose that the Brazilian government has committed to build in northern Brazil. The royalty-bearing license granted by iBio covers the nations of Latin America, the Caribbean and Africa. iBio retains the right to sell the products developed under the license and collaboration agreement in any other territory with a royalty back to Bio-Manguinhos/Fiocruz.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
IBIO:US $0.40 USD -0.015

IBIO Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for IBIO.
View Industry Companies
 

Industry Analysis

IBIO

Industry Average

Valuation IBIO Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 44.2x
Price/Book 3.9x
Price/Cash Flow NM Not Meaningful
TEV/Sales 37.1x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact IBIO INC, please visit www.ibioinc.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.